Trillium Health Care Products Expands CDMO Capacity and Executive Team

• Trillium Health Care Products has appointed three senior executives and completed a new expansion to its CDMO manufacturing capabilities.

• The expansion includes a 5,900 sq ft GMP suite and 10,000L integrated high-shear manufacturing tanks for liquids and semi-solids.

Trillium Health Care Products has announced the appointment of three new senior executives and the completion of a major expansion to its liquid and semi-solid manufacturing facility. The developments are aimed at supporting the company’s long-term growth as a contract manufacturing partner in North America’s consumer health sector.

The announcement, made on 3 June 2025, confirmed that Michael Pignatiello has joined as Chief Executive Officer. He is joined by Martin Quesnel as Chief Operating Officer and Sherif Elkholy as Chief Financial Officer. The new team brings industry experience from Bayer, Merck, Catalent, GlaxoSmithKline, and Pfizer.

Trillium has also completed the buildout of a 5,900 square foot Good Manufacturing Practice (GMP) suite dedicated to liquids and semi-solids. The facility features 10,000L integrated high-shear manufacturing tanks, aimed at supporting the production of fast-growing OTC brands and expanding the company’s CDMO capabilities.

According to the release, Trillium plans to pursue strategic acquisitions to grow its footprint across North America and broaden access to new product technologies. The company is backed by Avista Healthcare Partners, which has invested over $8 billion in healthcare businesses globally.

“We are excited to welcome Mike, Marty and Sherif to the team,” said Alex Yu, Partner at Avista. “Their knowledge of the consumer healthcare and pharmaceutical sectors… will be instrumental in executing our growth strategy and elevating Trillium as a best-in-class operator and industry leader.”